Aquila Bioscience

Founded in 2012 at the University Galway, Ireland, Aquila Bioscience's focus is to develop nature inspired safe and environmentally sustainable technologies to protect humans and animals from pathogens. Aquila Bioscience's Pathogen Capture Technology (PCT) was developed in collaboration with the Defence Forces Ireland and the Czech University of Defence to protect first responders against biothreat agents. It has been demonstrated to be effective against a number of bacteira, viruses, fungi and biotoxins that pose threat to human and animal health. Aquila Bioscience have successfully applied this technology and launched the first Aquila Bioscience product, "ABD device". It is free from alcohol and toxic chemicals, and is a biodegradable Class I device that safely captures, removes and neutralizes harmful pathogens and viral infections like coronavirus from the skin including eyes nose and mouth plus sensitive and hard surfaces such as screens, workbenches, desks etc. Our experienced R&D team bring together a range of science disciplines, bridging Glycobiology, Immunology, Microbiology, biochemistry and analytical chemistry.

• Employees2
• Founded2012
• Annual Revenue$5854000